154356-96-4

Usage

Uses

Used in Pharmaceutical Industry:
(4-Chlorophenyl)[4-(1-Methylethoxy)phenyl]Methanone (Fenofibrate Impurity) is used as a reference compound for the quality control and analysis of Fenofibrate in the pharmaceutical industry. Its presence in the drug formulation can be monitored and controlled to ensure the safety, efficacy, and purity of the antihyperlipoproteinemic drug Fenofibrate.
Used in Research and Development:
In the field of research and development, (4-Chlorophenyl)[4-(1-Methylethoxy)phenyl]Methanone (Fenofibrate Impurity) serves as a valuable compound for studying the photochemical reactions and stability of Fenofibrate. This understanding can help in the development of improved drug formulations and the optimization of storage and handling conditions to minimize the formation of impurities.
Used in Quality Control Laboratories:
(4-Chlorophenyl)[4-(1-Methylethoxy)phenyl]Methanone (Fenofibrate Impurity) is utilized as a reference material in quality control laboratories to validate and calibrate analytical methods for the detection and quantification of impurities in Fenofibrate drug products. This ensures that the drug meets the required standards for quality and safety before it is released for clinical use.

Upstream product

• 122-01-0 4-chloro-benzoyl chloride 
• 153624-46-5 4-(isopropoxy)phenylboronic acid 
• 42017-89-0 fenofibric acid 

Relevant academic research and scientific papers

A laser flash photolysis study of fenofibric acid in aqueous buffered media: Unexpected triplet state inversion in a derivative of 4-alkoxybenzophenone

Laser excitation of aqueous solutions of fenofibric acid (FA) at pH 7.4 show the formation of two reaction intermediates, the triplet state and the hydrated electron. The former is longer lived in water than in acetonitrile; its anionic form decays irreve

A laser flash photolysis study on fenofibric acid

Fenofibric acid (FA) is a photosensitizing drug used in the treatment of hyperlipidemia. This compound follows two different photodegradation pathways: the free acid exhibits the typical benzophenone photoreactivity, while its sodium salt undergoes photodecarboxylation via a triplet biradical, that undergoes intramolecular electron transfer to form a carbanion, or cyclization to give an intramolecular light-absorbing transient (LAT). The obtained photoproducts are explained as the result of protonation of the carbanion, ring opening of the LAT with rearrangement or oxygen trapping of any of the triplet intermediates. The above mechanism is supported by direct detection of the triplet state of FA and two long-lived intermediates in laser flash photolysis experiments. The triplet lifetime of the carboxylate form in methanol is 0.06 μs; by contrast, in the case of the free acid, it is 10 times longer. The benzophenone moiety is clearly the key chromophore involved in the photobehavior of FA.

Direct Hydrodecarboxylation of Aliphatic Carboxylic Acids: Metal- and Light-Free

A mild and inexpensive method for direct hydrodecarboxylation of aliphatic carboxylic acids has been developed. The reaction does not require metals, light, or catalysts, rendering the protocol operationally simple, easy to scale, and more sustainable. Crucially, no additional H atom source is required in most cases, while a broad substrate scope and functional group tolerance are observed.

Analogues of fenarimol are potent inhibitors of trypanosoma cruzi and are efficacious in a murine model of chagas disease

We report the discovery of nontoxic fungicide fenarimol (1) as an inhibitor of Trypanosoma cruzi (T. cruzi), the causative agent of Chagas disease, and the results of structure-activity investigations leading to potent analogues with low nM IC50s in a T. cruzi whole cell in vitro assay. Lead compounds suppressed blood parasitemia to virtually undetectable levels after once daily oral dosing in mouse models of T. cruzi infection. Compounds are chemically tractable, allowing rapid optimization of target biological activity and drug characteristics. Chemical and biological studies undertaken in the development of the fenarimol series toward the goal of delivering a new drug candidate for Chagas disease are reported.